The agent successfully gathered core information about BOTOX's purpose, target uses, pricing assistance programs, and competitive positioning by repeatedly fetching the homepage. However, the site's refusal to list actual prices and lack of comparative efficacy data meant the agent had to fill gaps by flagging what was missing rather than what was present.

• ›The site was traversed entirely through repeated homepage fetches (steps [1], [3], [5], [7] all from memory) rather than by following links; the agent did not discover a navigation path within botox.com itself, suggesting limited internal linking or discoverability of subsidiary pages.
• ›Pricing information was deliberately hidden behind an external 'cost estimator tool'—the site refused to publish actual costs, forcing the agent to report only the BOTOX Complete assistance program details (capped reimbursements and eligibility exclusions).
• ›Competitor names (Dysport, Xeomin, Myobloc, Jeuveau, Daxxify, Letybo) were explicitly listed on the site, but no comparative efficacy, safety, or clinical outcome data was published—the agent correctly flagged this gap as a confusing omission.
• ›The site emphasized BOTOX's 35+ years of clinical experience and 10+ million treatments as differentiators, but did not explain *why* the non-interchangeable dosing or clinical approach makes it superior, leaving the agent to note the claim was not substantiated.
• ›The site's tone and structure revealed it targets medical professionals and informed patients rather than general consumers—cosmetic applications were mentioned but received minimal emphasis, which the agent correctly identified as an asymmetry in positioning.